Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5913484 | 0.98 | ACHE (0.53) | PRKCIACHEMAOAMAOBCYP19A1 | |
| Phenol SCHEMBL28072627 | 0.88 | PRKCI (0.50) | PRKCIACHEMAOAMAOBBCHE | |
| SCHEMBL10646371 | 0.88 | BCHE (0.54) | MAOAMAOBCYP19A1BCHE | |
| SCHEMBL13243056 | 0.86 | TSHR (0.49) | PRKCIACHEMAOAMAOBCYP19A1 | |
| SCHEMBL7766011 | 0.85 | HRH3 (0.56) | ACHEHRH3BCHECYP1A2CYP2D6 | |
| SCHEMBL1206253 | 0.85 | TSHR (0.50) | MAOAMAOBCYP19A1HRH3BCHE | |
| SCHEMBL10647922 | 0.82 | MAOA (0.57) | MAOAMAOBCYP19A1BCHEAOC3 | |
| SCHEMBL3146615 | 0.82 | CHRNB2 (0.50) | MAOAMAOBCYP19A1GRIN2DGRIN3B | |
| SCHEMBL29943821 | 0.81 | MAOA (0.55) | MAOAMAOBCYP19A1BCHEAOC3 | |
| SCHEMBL249429 | 0.81 | MAOA (0.55) | MAOAMAOBCYP19A1BCHEAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398783-A1 | Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof | GISMO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4398902-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF | Gismo Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023038876-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF | GISMO THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-3473099-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | Samumed, LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2016131789-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-25 | — | — | WO | disclosed |
| EP-3056202-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-0884310-B1 | Quinazolin-4-one ampa antagonists | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | BAYER HEALTHCARE AG | 2005-07-28 | — | — | US | disclosed |
| US-6921764-B2 | Thieno-pyrimidin-4-one AMPA antagonists | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6627755-B1 | Neurodegenerative, psychological, and nervous system disorder; drug abuse, alcoholism | PFIZER INC | 2003-09-30 | — | — | US | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
| EP-0884310-A1 | Quinazolin-4-one ampa antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | PRKCI 501/4885ACHE 4763/4885MAOA 4008/4885 |
| US-20240398783-A1 | Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof | PRNP, GBA1, GBA3 | PRKCI 4441/4885ACHE 60/4885MAOA 1226/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | PRKCI 311/4885ACHE 4350/4885MAOA 4218/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | PRKCI 488/4885ACHE 4778/4885MAOA 4062/4885 |
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | GRIN1, GRIK1, GRIN3A | PRKCI 1880/4885ACHE 184/4885MAOA 1329/4885 |
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | SERPINB1, ELANE, MPO | PRKCI 2976/4885ACHE 549/4885MAOA 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.